2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1559

Residual Disease Activity in Psoriatic Arthritis Triggers Treatment Adjustment in Only a Quarter of Patients in Daily Clinical Practice
Abstract Number: 1560

Predictors of Long-Term Modified Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated with Adalimumab
Abstract Number: 1561

Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Biologic-NaïVe Psoriatic Arthritis
Abstract Number: 1562

Biological DMARD Efficacy in Psoriatic Arthritis: A Systematic Review and Meta-Analysis on ACR Response Criteria, PASI Response Criteria, HAQ-DI, Enthesitis and Dactylitis Outcomes
Abstract Number: 1563

Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
Abstract Number: 1564

Treatment Patterns, Survival and Long-Term Effectiveness of Biological Agents in Psoriatic Arthritis Patients
Abstract Number: 1565

Depression and Fatigue in Patients with Ankylosing Spondylitis
Abstract Number: 1566

Elevated IL-1 Expression Levels in Mesenchymal Stem Cells Derived from Spondyloarthitis Patients Might be Linked to Increased Osteoblast Mineralization
Abstract Number: 1567

A Mitogen-Associated Protein Kinase (MAPK) Associated Kinase 2 Inhibitor Decreases in Vitro Th17 and Monocyte Inflammatory Responses in Spondyloarthritis
Abstract Number: 1568

Existence of IL-6 and IL-17 Mediated Inflammation Amplifier Loop in Reactive Arthritis
Abstract Number: 1569

Isotretinoin Induced Seronegative Spondyloarthropathy: Magnetic Resonance Imaging As Diagnostic and Prognostic Biomarker
Abstract Number: 1570

Monocytes from Male Patients with Ankylosing Spondylitis Display Decreased Osteoclastogenesis and Decreased RANKL/OPG Ratio
Abstract Number: 1571

Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Abstract Number: 1572

MHC Associations of Ankylosing Spondylitis in East Asians Are Driven By HLA-B Amino-Acid Position 97, Confirming Findings in European Descent Subjects
Abstract Number: 1573

In Vivo Phosphorylation of p38 in Monocytes Is Enhanced in Patients with Axial Spondyloarthritis (axSpA) at the Time of Diagnosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].